Comprehensive animal models, active ingredient profiling, and high-standard clinical translation configured for Doha and GCC biomedical hubs.
Aligning translational medicine, Qatar National Vision 2030, and worldwide GLP compliance standards.
Driven by Qatar Foundation, Sidra Medicine, and Qatar Biobank, Doha is leading the MENA region in precision therapeutics and genomic medicine. However, local vivarium resources require scalable, international ODM animal study partnerships to conduct high-throughput chronic toxicity, pharmacokinetics (PK/PD), and oncology efficacy profiling.
Global pharmaceutical development faces mounting regulatory scrutiny under OECD and FDA guidelines. Preclinical testing now demands reproducible rodent and non-rodent efficacy models, automated behavioral tracking, and integrated bioanalytical fingerprinting. Yineng Pharma bridges lab R&D with turnkey CDMO capability, lowering the cost per data point.
Translating preclinical dossiers for submission to the Qatar Ministry of Public Health (MoPH) and the Gulf Health Council demands uncompromised GLP adherence. Our contract research programs deliver fully audited electronic datasets, histopathology imaging, and toxicological thresholds ready for multi-region clinical trial authorization (CTA/IND).
The disease landscape in Qatar and the Arabian Peninsula exhibits distinct epidemiologic challenges—most notably elevated incidences of Type 2 Diabetes Mellitus, non-alcoholic fatty liver disease (NAFLD/NASH), cardiovascular syndrome, and autoimmune disorders. Standard global rodent models often fail to capture specific dietary stress or phenotypic progressions relevant to local cohorts.
Yineng Pharma designs customized ODM animal models specifically addressing these regional clinical targets:
By outsourcing complex animal experimental modules to Yineng Pharma’s specialized Changsha R&D facility, Doha pharmaceutical companies and research universities eliminate heavy domestic capital expenditure on animal barrier housing, automated micro-CT, and continuous veterinary compliance oversight.
Full Confidentiality & Raw Data Integrity: Under strict NDA protocols, our international clients retain 100% intellectual property ownership, backed by real-time audit trails, frozen biospecimen transfers, and digital slides.
A structured, stage-gated preclinical methodology engineered to de-risk candidate molecules before Phase I initiation.
Indication alignment, in vitro cytotoxicity pre-screening, model phenotype identification (wild-type, transgenic, or induced disease models), and protocol sign-off with IACUC standards.
Acute tolerability, bio-distribution, dose-ranging efficacy, plasma concentration over time (LC-MS/MS), and continuous functional and physiological telemetry monitoring.
Hematology, biochemical liver/kidney markers, organ indices, microtome tissue slicing, H&E staining, immunohistochemistry (IHC), and OECD-compliant NOAEL determination.
Comprehensive biostatistical study report, regulatory validation for GCC/FDA/NMPA filing, process parameter optimization, and seamless scale-up into pilot CDMO manufacturing.
As global standards shift under the 3Rs (Replacement, Reduction, Refinement), our preclinical platforms are integrating AI computer vision for non-invasive behavior monitoring, organ-on-a-chip validation arrays, and machine-learning metabolomic prediction. This future-proof framework guarantees our Doha partners stay ahead of regulatory demands while shortening the cycle from hit discovery to clinical candidate proof.
Explore our complete library of entrusted R&D modules, analytical validations, and customized production capabilities.
Key regulatory, logistical, and scientific considerations for partners engaging our CRO/CDMO services from Doha.
All in vivo animal protocols conform strictly to international AAALAC guidelines, the Guide for the Care and Use of Laboratory Animals, and our institutional IACUC committee oversight. For studies destined for Qatari or European regulatory filings, animal housing environmental controls, anesthesia protocols, and humane endpoints are fully audited and documented.
Yes. We have established cold-chain, temperature-logged logistical pathways compliant with international biological sample transport rules. Our customs documentation unit handles customs clearance, import permits for novel research chemicals, and plant phytosanitary certifications smoothly into our Changsha central laboratories.
We routinely execute studies on DIO (Diet-Induced Obesity) mice, db/db and ob/ob rodents, STZ-induced diabetic models, and methionine-choline deficient (MCD) diet-induced non-alcoholic steatohepatitis (NASH) models. We evaluate insulin sensitivity (OGTT/ITT), hyperlipidemia, inflammatory cytokines, and quantitative hepatic steatosis via histological scoring.
Confidentiality is our operational cornerstone. Prior to receiving molecular structures, proprietary herbal ratios, or process blueprints, a bilateral, legally binding Non-Disclosure Agreement (NDA) is executed. All digital records, chromatography raw data, and histopathology scans are stored on isolated, encrypted servers with restricted project team access.
Beyond contract research (CRO), we operate a high-capacity contract development and manufacturing organization (CDMO). Once efficacy is confirmed in vivo, our pilot manufacturing lines can formulate granules, oral liquids, softgels, tablets, and powders under strict GMP conditions ready for clinical supply or commercial launch.
From protocol freeze and compound receipt to animal acclimatization, in-life dosing, clinical pathology, terminal necropsy, histopathology slide prep, and certified toxicologist QA review, a standard GLP-compliant 28-day repeated-dose study package typically spans 8 to 12 weeks, concluding with an audit-ready final report.